A detailed history of Barclays PLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 939,336 shares of VRTX stock, worth $383 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
939,336
Previous 939,336 -0.0%
Holding current value
$383 Million
Previous $437 Million -0.0%
% of portfolio
0.12%
Previous 0.12%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$460.0 - $505.78 $43.1 Million - $47.4 Million
93,674 Added 11.08%
939,336 $437 Million
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $11.1 Million - $13.7 Million
28,247 Added 3.46%
845,662 $396 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $4.34 Million - $4.75 Million
10,656 Added 1.32%
817,415 $342 Million
Q4 2023

Feb 15, 2024

BUY
$343.0 - $410.68 $188,650 - $225,874
550 Added 0.07%
806,759 $328 Million
Q3 2023

Nov 07, 2023

BUY
$338.18 - $362.46 $57.6 Million - $61.7 Million
170,224 Added 26.77%
806,209 $280 Million
Q2 2023

Aug 03, 2023

BUY
$314.42 - $351.91 $62.9 Million - $70.4 Million
199,923 Added 45.85%
635,985 $224 Million
Q1 2023

May 04, 2023

SELL
$283.23 - $323.1 $49.8 Million - $56.8 Million
-175,725 Reduced 28.72%
436,062 $137 Million
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $56.8 Million - $63.9 Million
198,887 Added 48.17%
611,787 $177 Million
Q3 2022

Nov 03, 2022

BUY
$273.83 - $305.53 $8.71 Million - $9.72 Million
31,812 Added 8.35%
412,900 $120 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $44.9 Million - $55.9 Million
-190,947 Reduced 33.38%
381,088 $107 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $1.9 Million - $2.23 Million
-8,563 Reduced 1.47%
572,035 $149 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $2.11 Million - $2.66 Million
11,895 Added 2.09%
580,598 $128 Million
Q3 2021

Nov 09, 2021

BUY
$181.39 - $202.99 $26.8 Million - $29.9 Million
147,497 Added 35.02%
568,703 $103 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $8.42 Million - $9.93 Million
44,907 Added 11.93%
421,206 $84.9 Million
Q1 2021

May 13, 2021

SELL
$207.02 - $241.31 $14.4 Million - $16.8 Million
-69,698 Reduced 15.63%
376,299 $80.9 Million
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $12.4 Million - $16.5 Million
59,702 Added 15.46%
445,997 $105 Million
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $13.6 Million - $16.1 Million
53,203 Added 15.97%
386,295 $105 Million
Q2 2020

Aug 12, 2020

SELL
$225.48 - $295.8 $78.7 Million - $103 Million
-349,050 Reduced 51.17%
333,092 $96.7 Million
Q1 2020

May 13, 2020

SELL
$199.77 - $247.81 $16.7 Million - $20.8 Million
-83,769 Reduced 10.94%
682,142 $162 Million
Q4 2019

Feb 10, 2020

BUY
$166.71 - $223.91 $57.1 Million - $76.7 Million
342,430 Added 80.86%
765,911 $168 Million
Q3 2019

Nov 14, 2019

BUY
$166.23 - $187.09 $10.9 Million - $12.2 Million
65,385 Added 18.26%
423,481 $71.7 Million
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $14.8 Million - $17.2 Million
90,157 Added 33.65%
358,096 $65.7 Million
Q1 2019

May 15, 2019

SELL
$163.73 - $194.7 $12.6 Million - $15 Million
-77,090 Reduced 22.34%
267,939 $49.3 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $16.7 Million - $21.2 Million
-110,037 Reduced 24.18%
345,029 $57.2 Million
Q3 2018

Nov 14, 2018

BUY
$167.73 - $192.74 $25.5 Million - $29.3 Million
151,996 Added 50.15%
455,066 $87.7 Million
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $23.7 Million - $27.6 Million
-162,581 Reduced 34.91%
303,070 $51.5 Million
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $9.67 Million - $11.3 Million
63,770 Added 15.87%
465,651 $75.9 Million
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $18.4 Million - $20.9 Million
134,325 Added 50.2%
401,881 $60.2 Million
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $39.6 Million - $43.4 Million
267,556
267,556 $40.7 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.